Related Experiment Videos
Trial of inactivated Japanese encephalitis vaccine in children with underlying diseases
Insights
Japanese encephalitis (JE) vaccination is safe and effective in children, including those with underlying health conditions. Two doses of the inactivated JE vaccine induced strong antibody responses and seroconversion in all pediatric participants.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- Japanese encephalitis (JE) is a serious mosquito-borne viral disease.
- Vaccination is crucial for preventing JE, but its efficacy in specific pediatric populations requires study.
Purpose of the Study:
- To evaluate the immunogenicity and safety of an inactivated Japanese encephalitis vaccine in children.
- To assess antibody responses in children with underlying diseases compared to healthy children.
Main Methods:
- The study involved 139 children with underlying diseases and 42 healthy children.
- Participants received two doses of the inactivated JE vaccine.
- Antibody responses were measured using neutralization tests before and after vaccination.
Main Results:
- All participants achieved seroconversion one month after the second vaccine dose.
- High neutralizing antibody titers against JE virus were observed in all vaccinees.
- The vaccine was well-tolerated, with only one healthy child experiencing mild fever; no severe adverse events or reactions were noted in any participant, including those with underlying conditions.
Conclusions:
- The current inactivated Japanese encephalitis vaccine is safe for pediatric use.
- The vaccine effectively induces a robust immune response, even in children with underlying health conditions.
- This supports the use of JE vaccination in diverse pediatric groups.
Abstract:
Two shots of inactivated Japanese encephalitis (JE) vaccine were given to children, 139 with underlying diseases and 42 healthy, and their antibody responses were studied by the neutralization test. Before vaccination, most of the vaccinees did not have antibody against JE virus. One month after the second vaccination, they were all seroconverted and showed considerably high neutralizing titres. One healthy child developed fever on the day of vaccination without any severe symptoms afterwards, and no side reactions were observed in the handicapped children. These results suggest that the current JE vaccine is safe and can induce a strong immune response even in handicapped children.